Cargando…

The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era

Detalles Bibliográficos
Autores principales:	Kockerols, Camille C.B., Geelen, Inge, Levin, Mark-David, Janssen, Jeroen J.W.M., Dinmohamed, Avinash G., Hoogendoorn, Mels, Cornelissen, Jan J., Westerweel, Peter E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335097/ https://www.ncbi.nlm.nih.gov/pubmed/35354254 http://dx.doi.org/10.3324/haematol.2021.280501

Ejemplares similares

High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population
por: Kockerols, Camille C.B., et al.
Publicado: (2023)

Treatment outcome in a population-based, ‘real-world’ cohort of patients with chronic myeloid leukemia
por: Geelen, Inge G.P., et al.
Publicado: (2017)

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
por: Kockerols, Camille C.B., et al.
Publicado: (2020)

Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
por: Kockerols, Camille C.B., et al.
Publicado: (2022)

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018
por: Maas, Carolien C. H. M., et al.
Publicado: (2021)

Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity
por: Janssen, Lando, et al.
Publicado: (2020)

Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia
por: Ossenkoppele, Gert J, et al.
Publicado: (2013)

New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
por: Westerweel, Peter E., et al.
Publicado: (2019)

The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach
por: Ector, Geneviève ICG, et al.
Publicado: (2020)

Primary Epstein–Barr virus infection diffusing F(18)-fluorodeoxyglucose-positron emission tomography/computed tomography response monitoring of Hodgkin’s disease: a case report
por: Balink, Hans, et al.
Publicado: (2014)

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia
por: Leitch, Calum, et al.
Publicado: (2016)

Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review
por: Castillo, Dan Ran, et al.
Publicado: (2022)

Myeloid Sarcoma Developing in Prexisting Hydroxyurea-Induced Leg Ulcer in a Polycythemia Vera Patient
por: Nafil, Hatim, et al.
Publicado: (2013)

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms
por: Barbui, Tiziano, et al.
Publicado: (2018)

Targeting matrix metallopeptidase 2 by hydroxyurea selectively kills acute myeloid mixed-lineage leukemia
por: Wang, Ruiheng, et al.
Publicado: (2022)

Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors. The first molecular targeted treatment
por: Bumbea, H, et al.
Publicado: (2010)

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era
por: Renault, Ilana Zalcberg, et al.
Publicado: (2011)

Hydroxyurea Induced Perimalleolar Ulcers
por: Saravu, Kavitha, et al.
Publicado: (2006)

Mutagenic and Genotoxic Effect of Hydroxyurea
por: Santos, Jean L., et al.
Publicado: (2011)

Blue Lunula Related with Hydroxyurea
por: Üsküdar Teke, Hava, et al.
Publicado: (2013)

The Cell Killing Mechanisms of Hydroxyurea
por: Singh, Amanpreet, et al.
Publicado: (2016)

Hydroxyurea-induced Tooth Discoloration
por: Okuyucu, Muhammed, et al.
Publicado: (2020)

Hydroxyurea—The Good, the Bad and the Ugly
por: Musiałek, Marcelina W., et al.
Publicado: (2021)

Hydroxyurea-Induced Acute Pancreatitis
por: Bath, Harjot, et al.
Publicado: (2022)

Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
por: Hochhaus, Andreas, et al.
Publicado: (2020)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
por: Jain, Parveen, et al.
Publicado: (2013)

Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia
por: Boons, Christel CLM, et al.
Publicado: (2014)

Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors
por: Piekarska, Agnieszka, et al.
Publicado: (2016)

Native aortic valve endocarditis with Morganella morganii in a patient with multiple myeloma and valvular amyloidosis: a case report
por: van Bentum, Renée, et al.
Publicado: (2019)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Nitric Oxide Generation from Hydroxyurea via Copper‐catalyzed Peroxidation and Implications for Pharmacological Actions of Hydroxyurea
por: Sato, Keizo, et al.
Publicado: (1997)

Proceedings: DNA synthesis in the presence of hydroxyurea.
por: Brown, J. S., et al.
Publicado: (1974)

Melanonychia and skin hyperpigmentation with hydroxyurea therapy
por: Koley, Sankha, et al.
Publicado: (2010)

Widespread Natural Occurrence of Hydroxyurea in Animals
por: Fraser, David I., et al.
Publicado: (2015)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

The Use of Hydroxyurea in the Treatment of COVID-19
por: Foster, Melissa Robin Bowman, et al.
Publicado: (2021)

P565: REAL-WORLD DATA AS SUPPLEMENTARY CONTROLS FOR THE PROSPECTIVE RANDOMIZED HOVON-103 TRIAL IN INTENSIVELY TREATED ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS
por: Hermans, Sjoerd, et al.
Publicado: (2023)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia
por: Verhagen, Noor E., et al.
Publicado: (2023)

Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors
por: Sasaki, Koji, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5l55tr506if089r2ta0rbp75us